Xiaoyan lidan formula ameliorates α-naphthylisothiocyanate-induced intrahepatic cholestatic liver injury in rats as revealed by non-targeted and targeted metabolomics
Xiaoyan lidan formula ameliorates α-naphthylisothiocyanate-induced intrahepatic cholestatic liver injury in rats as revealed by non-targeted and targeted metabolomics
复制标题
非靶向和靶向代谢组学显示消炎利胆方可改善α-萘基异硫氰酸酯诱导的大鼠肝内胆汁淤积性肝损伤
DOI：
10.1016/j.jpba.2019.112966
复制
发表时间：
2020-02-03
影响因子：
3.4
通讯作者：
Zhu, Chenchen
中科院分区：
文献类型：
--
作者：
Zhang, Runjing;Huang, Tao;Zhu, Chenchen
肝内胆汁淤积症（Intrahepatic Cholestasis，ICP）是一种以胆汁酸中毒为主要表现的肝损害综合征，目前尚无有效的治疗方法。消炎利胆方是临床上用于治疗胆汁淤积性肝胆疾病的传统方剂。但其机制仍不清楚。本研究采用基于UHPLC-Q-TOF-MS/MS的非靶向代谢组学方法结合基于UHPLC-MS/MS的胆汁酸靶向代谢组学方法，探讨XYLDF对α-萘异硫氰酸酯（ANIT）诱导的肝内胆汁淤积大鼠的作用机制。结果表明，在不同浓度下，共检测到39种内源性代谢产物，差异显著（VIP > 1.00，P
Intrahepatic cholestasis is a clinical syndrome of liver damage with systemic circulation and intrahepatic accumulation of excessive toxic bile acids without effective therapeutic methods so far. Xiaoyan Lidan Formula (XYLDF), a traditional Chinese prescription, has long been clinically applied for hepatobiliary disorders due to cholestasis. But its mechanism remains unknown. In this study, a non-targeted metabolomics approach based on UHPLC-Q-TOF-MS/MS combined with a bile acids (BAs) - targeted metabolomics approach based on UHPLC-MS/MS were performed to elucidate the functional mechanisms of XYLDF on alpha-naphthylisothiocyanate(ANIT)-induced intrahepatic cholestasis rats. The results showed that a total of 39 endogenous metabolites with significant difference (VIP > 1.00, P